Literature DB >> 29283087

Preoperative sarcopenia status is associated with lymphovascular invasion in upper tract urothelial carcinoma patients treated with radical nephroureterectomy.

Tadatsugu Anno1, Eiji Kikuchi1, Keishiro Fukumoto1, Koichiro Ogihara1, Mototsugu Oya1.   

Abstract

INTRODUCTION: Sarcopenia is a novel concept representing skeletal muscle wasting and has been identified as a prognostic factor for several cancers. The aims of this study were to evaluate the prognostic significance of sarcopenia and the relationship between sarcopenia and poor pathological findings in upper tract urothelial carcinoma (UTUC) patients who underwent radical nephroureterectomy (RNU).
METHODS: We identified 123 UTUC patients who underwent RNU between 2003 and 2014. We assessed sarcopenia by measuring the area of skeletal muscle at the third lumber vertebra on preoperative computed tomography scans. Sarcopenia was classified based on a sex-specific consensus definition. We investigated whether sarcopenia predicts clinical outcomes, such as cancer death and poor pathological findings at RNU.
RESULTS: A total of 50 (40.7%) patients had sarcopenia. In a multivariate Cox regression analysis, sarcopenia was not associated with cancer-specific survival (CSS), and lymphovascular invasion (LVI) (hazard ratio 5.88; p=0.002) was the only independent risk factor for CSS. A multivariate logistic regression analysis showed that sarcopenia independently correlated with the LVI status (odds ratio 2.36; p=0.025). LVI was positive in 27 of 50 (54%) and 25 of 73 (34%) patients with and without sarcopenia, respectively (p=0.029).
CONCLUSIONS: Preoperative sarcopenia predicted the LVI status, which was a strong prognostic factor for UTUC patients after RNU.

Entities:  

Year:  2017        PMID: 29283087      PMCID: PMC5869038          DOI: 10.5489/cuaj.4786

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  32 in total

Review 1.  Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature.

Authors:  Giovanni Lughezzani; Maximilian Burger; Vitaly Margulis; Surena F Matin; Giacomo Novara; Morgan Roupret; Shahrokh F Shariat; Christopher G Wood; Richard Zigeuner
Journal:  Eur Urol       Date:  2012-02-23       Impact factor: 20.096

2.  Prognostic indicators for upper tract urothelial carcinoma after radical nephroureterectomy: the impact of lymphovascular invasion.

Authors:  Mark S Godfrey; Gina M Badalato; Gregory W Hruby; Mani Razmjoo; James M McKiernan
Journal:  BJU Int       Date:  2012-02-07       Impact factor: 5.588

Review 3.  Urothelial carcinoma of the bladder and the upper tract: disparate twins.

Authors:  David A Green; Michael Rink; Evanguelos Xylinas; Surena F Matin; Arnulf Stenzl; Morgan Roupret; Pierre I Karakiewicz; Douglas S Scherr; Shahrokh F Shariat
Journal:  J Urol       Date:  2012-09-27       Impact factor: 7.450

Review 4.  Molecular mechanism of sarcopenia and cachexia: recent research advances.

Authors:  Kunihiro Sakuma; Wataru Aoi; Akihiko Yamaguchi
Journal:  Pflugers Arch       Date:  2017-01-19       Impact factor: 3.657

5.  Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.

Authors:  Lisa Martin; Laura Birdsell; Neil Macdonald; Tony Reiman; M Thomas Clandinin; Linda J McCargar; Rachel Murphy; Sunita Ghosh; Michael B Sawyer; Vickie E Baracos
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

6.  Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study.

Authors:  Hiroki Ishihara; Tsunenori Kondo; Kenji Omae; Toshio Takagi; Junpei Iizuka; Hirohito Kobayashi; Yasunobu Hashimoto; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2016-07-15       Impact factor: 3.402

7.  Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.

Authors:  H Kitamura; T Tsukamoto; T Shibata; N Masumori; H Fujimoto; Y Hirao; K Fujimoto; Y Kitamura; Y Tomita; K Tobisu; M Niwakawa; S Naito; M Eto; Y Kakehi
Journal:  Ann Oncol       Date:  2014-03-24       Impact factor: 32.976

Review 8.  Prognostic Factors of Overall Survival in Upper Urinary Tract Carcinoma: A Systematic Review and Meta-analysis.

Authors:  Fausto Petrelli; Mohamed Ismail Yasser Hussein; Ivano Vavassori; Sandro Barni
Journal:  Urology       Date:  2016-08-08       Impact factor: 2.649

Review 9.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

Authors: 
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321

10.  Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.

Authors:  Younak Choi; Do-Youn Oh; Tae-Yong Kim; Kyung-Hun Lee; Sae-Won Han; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

View more
  2 in total

1.  Sarcopenia as a significant predictive factor of neutropenia and overall survival in urothelial carcinoma patients underwent gemcitabine and cisplatin or carboplatin.

Authors:  Tetsuya Yumioka; Masashi Honda; Ryoma Nishikawa; Shogo Teraoka; Yusuke Kimura; Hideto Iwamoto; Shuichi Morizane; Katsuya Hikita; Atsushi Takenaka
Journal:  Int J Clin Oncol       Date:  2019-09-13       Impact factor: 3.402

2.  Sarcopenia is associated with survival in patients with urothelial carcinoma treated with systemic chemotherapy.

Authors:  Ryutaro Shimizu; Masashi Honda; Shogo Teraoka; Tetsuya Yumioka; Noriya Yamaguchi; Bunya Kawamoto; Hideto Iwamoto; Shuichi Morizane; Katsuya Hikita; Atsushi Takenaka
Journal:  Int J Clin Oncol       Date:  2021-10-04       Impact factor: 3.402

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.